reports
Sanofi: Information concerning the total number of voting rights and s...
Sanofi: Information concerning the total number of voting rights and shares - March 2025 Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of €2,452,461,656Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Registry und...
Sanofi: Informations relatives au nombre de droits de vote et d'action...
Sanofi: Informations relatives au nombre de droits de vote et d'actions – Mars 2025 Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financiers SanofiSociété anonyme au capital de 2 452 461 656 euros Siège social : 46, avenue de la Grande Armée - 75017 Paris395 030 844 R.C.S. Paris DateNombre d’actions composant le capital Nombre réel de droits de vote (déduction faite des actions auto-détenues)Nombre théorique de droits de vote (y compris actions a...
AstraZeneca: 1 director
A director at AstraZeneca bought 700 shares at 143.310USD and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...
- Rune Majlund Dahl
Novo Nordisk (Buy, TP: DKK900.00) - Underlying soft GLP-1 sales
We forecast a soft Q1, with 17.3% LCY sales growth and 13.8% LCY operating profit growth due to subdued prescriptions. While we estimate Ozempic sales c0.5% below consensus, we are c1.2% above for Wegovy, as we include DKK1bn in sales related to Wegovy US inventories. We see likely relief from potential unchanged 2025 LCY guidance, supported by improved Wegovy supply and fading pressure from compounders. We reiterate our BUY and DKK900 target price.
Press Release: Annual General Meeting of April 30, 2025
Press Release: Annual General Meeting of April 30, 2025 Annual General Meeting of April 30, 2025 Approval of the financial statements for the fiscal year 2024Distribution of a cash dividend of €3.92 per share, with payment as of May 14, 2025Board composition: renewal of four Directors and ratification of the cooptation of Jean-Paul Kress Paris, April 30, 2025. The Combined General Shareholders’ Meeting of Sanofi was held on April 30, 2025, under the chairmanship of Frédéric Oudéa. All resolutions submitted to the vote were adopted by the shareholders. The General Meeting approved the ind...
Communiqué de presse : Assemblée Générale Annuelle du 30 avril 2025
Communiqué de presse : Assemblée Générale Annuelle du 30 avril 2025 Assemblée Générale Annuelle du 30 avril 2025 Approbation des comptes sociaux et des comptes consolidés de l’exercice 2024Distribution d’un dividende en numéraire de 3,92 euros par action, dont la mise en paiement interviendra le 14 mai 2025Composition du Conseil d’administration : renouvellement de quatre administrateurs et ratification de la cooptation de Jean-Paul Kress Paris, le 30 avril 2025. L’Assemblée Générale Mixte des actionnaires de Sanofi s’est réunie le 30 avril 2025, sous la présidence de Frédéric Oudéa. Tou...
Highlights of Renault Group's 2025 Annual General Meeting
Highlights of Renault Group's 2025 Annual General Meeting PRESS RELEASEApril 30 2025 HIGHLIGHTS OF RENAULT GROUP'S 2025 ANNUAL GENERAL MEETING Renault Group's Annual Shareholders’ Meeting took place today, April 30, in Boulogne-Billancourt. The 24 resolutions submitted to the vote of the shareholders were adopted.This annual meeting was also an opportunity for Jean-Dominique Senard, Chairman of the Board of Directors, and Luca de Meo, Chief Executive Officer of Renault Group, to thank the shareholders for their loyalty and to look back on the four years of Renaulution.More tha...
Les temps forts de l’Assemblée générale 2025 de Renault Group
Les temps forts de l’Assemblée générale 2025 de Renault Group COMMUNIQUÉ DE PRESSE30 avril 2025 LES TEMPS FORTS DE L’ASSEMBLEE GENERALE 2025 DE RENAULT GROUP L’Assemblée générale de Renault Group s’est déroulée aujourd’hui, 30 avril, à Boulogne-Billancourt. Les 24 résolutions soumises au vote des actionnaires ont été adoptées.Ce rendez-vous annuel fut également l’occasion pour Jean-Dominique Senard, Président du Conseil d’administration, et Luca de Meo, Directeur général de Renault Group, de remercier les actionnaires pour leur fidélité et de revenir sur les quatre années de la...
Communiqué de presse : Sanofi et CD&R finalisent la cession d’Opella e...
Communiqué de presse : Sanofi et CD&R finalisent la cession d’Opella et créent un leader mondial de la santé grand public Sanofi et CD&R finalisent la cession d’Opella et créent un leader mondial de la santé grand public Paris, le 30 avril 2025. Opella devient aujourd'hui un leader mondial indépendant de la santé grand public, marquant ainsi une étape décisive dans la stratégie de Sanofi. Sanofi annonce aujourd'hui la finalisation de la vente à CD&R d'une participation de contrôle de 50,0 % dans son activité de santé grand public Opella. Sanofi conserve une participation significative d...
Press Release: Sanofi and CD&R close Opella transaction, create global...
Press Release: Sanofi and CD&R close Opella transaction, create global consumer healthcare leader Sanofi and CD&R close Opella transaction, create global consumer healthcare leader Paris, April 30, 2025. Opella today becomes an independent global leader in consumer healthcare, marking a pivotal step in Sanofi's strategy. Sanofi announces today the closing of the sale to CD&R of a 50.0% controlling stake of its consumer healthcare business Opella. Sanofi retains a significant shareholding of Opella with a 48.2% stake. Bpifrance will own a 1.8% stake in Opella and will join the Board. The tr...
- Ahmed Ben Salem
DHLN DHL GROUP
FP TOTAL SE
EQNR EQUINOR ASA
MT ARCELORMITTAL SA
KNEBV KONE OYJ CLASS B
TKA TELEKOM AUSTRIA AG
FORTUM FORTUM OYJ
DAI DAIMLER AG
RXL REXEL SA
MMK MAYR-MELNHOF KARTON AG
OMV OMV AG
AMUN AMUNDI SA
SCHP SCHINDLER HOLDING AG PREF
SAN SANOFI
NEX NEXANS SA
VOW3 VOLKSWAGEN AG PREF
CAP CAPGEMINI SE
REP REPSOL SA
ASM ASM INTERNATIONAL N.V.
NEM NEMETSCHEK SE
KGX KION GROUP AG
AENA AENA SME SA
ANDR ANDRITZ AG
SNP PETROM S.A.
AZN ASTRAZENECA PLC
BP. BP P.L.C.
BBVA BANCO BILBAO VIZCAYA ARGENTARIA S.A.
ADYEN ADYEN NV
STLA STELLANTIS N.V.
UMG UNIVERSAL MUSIC GROUP NV
ATCO A ATLAS COPCO AB
STMN STRAUMANN HOLDING AG
GSK GSK PLC
P911 DR. ING. H.C. F. PORSCHE AKTIENGESELLSCHAFT
DSFIR KONINKLIJKE DSM N.V.
- Ahmed Ben Salem
DHLN DHL GROUP
FP TOTAL SE
EQNR EQUINOR ASA
MT ARCELORMITTAL SA
GALP GALP ENERGIA SGPS SA CLASS B
KNEBV KONE OYJ CLASS B
TKA TELEKOM AUSTRIA AG
FORTUM FORTUM OYJ
DAI DAIMLER AG
RXL REXEL SA
MMK MAYR-MELNHOF KARTON AG
OMV OMV AG
AMUN AMUNDI SA
SCHP SCHINDLER HOLDING AG PREF
SAN SANOFI
NEX NEXANS SA
VOW3 VOLKSWAGEN AG PREF
CAP CAPGEMINI SE
REP REPSOL SA
ASM ASM INTERNATIONAL N.V.
NEM NEMETSCHEK SE
AENA AENA SME SA
ANDR ANDRITZ AG
SNP PETROM S.A.
AZN ASTRAZENECA PLC
BP. BP P.L.C.
BBVA BANCO BILBAO VIZCAYA ARGENTARIA S.A.
ADYEN ADYEN NV
STLA STELLANTIS N.V.
UMG UNIVERSAL MUSIC GROUP NV
ATCO A ATLAS COPCO AB
STMN STRAUMANN HOLDING AG
GSK GSK PLC
P911 DR. ING. H.C. F. PORSCHE AKTIENGESELLSCHAFT
DSFIR KONINKLIJKE DSM N.V.
- Damien Choplain
- Martial Descoutures
- Damien Choplain
- Martial Descoutures
- Rune Majlund Dahl
Zealand Pharma (Buy, TP: DKK1000.00) - Focus on pipeline progression
We expect an uneventful Q1 report, with investor focus on top-line results from the dapiglutide phase Ib obesity trial (due in Q2), which could help provide clarity on the positioning of the molecule in obesity and inflammation. For petrelintide, we have reduced our peak sales forecast to cUSD10.0bn (cUSD10.8bn) on increased competition from GUBamy. We reiterate our BUY but have cut our target price to DKK1,000 (1,150).
- Damien Choplain
- Martial Descoutures
- ABGSC Healthcare Research
- Alexander Krämer
- Morten Larsen
- Damien Choplain
- Martial Descoutures
Press Release: When every second counts: Sanofi, McLaren Racing and Un...
Press Release: When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race Paris, April 29, 2025. Sanofi is proud to unveil an exciting new chapter in its mission to fight meningitis, as it expands its partnership with McLaren Racing for a powerful activation alongside United Autosports, the official racing partner of McLaren Automotive. This unique collaboration will...
Communiqué de presse :
Communiqué de presse : Quand chaque seconde compte : Sanofi, McLaren Racing et United Autosports s'unissent pour sensibiliser à la méningite aux 24 Heures du Mans Paris, le 29 avril 2025. Sanofi est fière de présenter une nouvelle étape significative dans sa mission de lutte contre la méningite, en renforçant son partenariat avec McLaren Racing et United Autosports, le partenaire officiel de course de McLaren Automotive. Cette collaboration exceptionnelle mettra en lumière le Drapeau Méningite — un symbole puissant de la lutte mondiale contre cette maladie — qui sera fièrement a...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.